Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $541

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $541

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $592 to $541.

byBenzinga Newsdesk

August 1, 2022

1 minute read

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $592 to $541.

Jefferies Downgrades Radius Global Infr to Hold, Raises Price Target to $15

By Benzinga Newsdesk

March 7, 6:05 AM

Jefferies analyst Jonathan Petersen downgrades Radius Global Infr (NASDAQ:RADI) from Buy to Hold and raises the price target from $14 to $15.

RADI

Skyworks Solutions Faces Multi-Quarter Headwinds: 5 Analysts Give Mixed Reviews

By Priya Nigam

May 9, 10:45 AM

Shares of Skyworks Solutions Inc (NASDAQ: SWKS) tanked in early trading on Tuesday, after the company reported downbeat quarterly results and issued a weak guidance.

AAPL

Analyst Ratings

BMO Capital Maintains Market Perform Rating for Aon: Here’s What You Need To Know

By Benzinga Insights

December 22, 1:00 PM

BMO Capital has decided to maintain its Market Perform rating of Aon (NYSE:AON) and lower its price target…

AON

Analyst Ratings

What 9 Analyst Ratings Have To Say About Splunk

By Benzinga Insights

May 23, 8:01 AM

Within the last quarter, Splunk (NASDAQ:SPLK) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

SPLK

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $541

Related Posts

Jefferies Downgrades Radius Global Infr to Hold, Raises Price Target to $15

Skyworks Solutions Faces Multi-Quarter Headwinds: 5 Analysts Give Mixed Reviews

BMO Capital Maintains Market Perform Rating for Aon: Here’s What You Need To Know

What 9 Analyst Ratings Have To Say About Splunk